Related Experiment Video
Updated: Nov 18, 2025
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.4K
Galactosemia: Towards Pharmacological Chaperones.
Samantha Banford1, Thomas J McCorvie2, Angel L Pey3
1South Eastern Health and Social Care Trust, Downpatrick BT30 6RL, UK.
Journal of Personalized Medicine
|February 10, 2021
Summary
Galactosemia, a rare metabolic disorder, causes lifelong disability due to inadequate dietary therapy. Pharmacological chaperones (PCs) offer a promising treatment to correct enzyme function and prevent disease progression.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Galactosemia is a rare inherited metabolic disease caused by gene mutations affecting galactose metabolism.
- Current dietary therapy is insufficient, leading to lifelong physical and cognitive disabilities.
- The core issue is reduced enzyme activity from misfolded proteins.
Purpose of the Study:
- To review the biochemical basis of galactosemia.
- To explore the potential of pharmacological chaperones (PCs) as a novel therapy.
- To discuss methods for discovering and applying PCs for galactosemia treatment.
Main Methods:
- Literature review of galactosemia's biochemical underpinnings.
- Analysis of the potential for pharmacological chaperones (PCs) in treating protein misfolding.
- Discussion of strategies for PC discovery and clinical implementation.
Main Results:
- Pharmacological chaperones (PCs) are small molecules that can correct protein misfolding.
- PCs hold theoretical promise for restoring enzyme function in galactosemia.
- No specific PCs have yet been identified for galactosemia treatment.
Conclusions:
- Pharmacological chaperones (PCs) represent a potential therapeutic strategy for galactosemia.
- Further research is needed to identify and develop PCs for clinical use.
- Clinical considerations are crucial for the future application of PCs in galactosemia management.
Keywords:
UDP-galactose 4′-epimerasedrug screeningenzymegalactokinasegalactose 1-phosphate uridylyltransferasegalactose metabolismgalactose mutarotaseligand bindingprotein degradationprotein misfoldingMore Related Videos
08:33Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
Published on: March 24, 2019
7.7K
14:56Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
Published on: March 10, 2012
18.9K
Related Concept Videos
01:27Glucose Transporters
26.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.6K
01:20Inborn Errors of Metabolism
523
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
523
01:24Oligosaccharide Assembly
3.2K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
3.2K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
390
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
390
01:15Hypoglycemia and Glucagon
534
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
534
01:22Lysosomal Hydrolases
4.2K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.2K